

Attorneys

Partner

- Stephen M. Goodman

Of Counsel

- Danielle L. Schechner

Pryor Cashman Represents Marina Biotech, Inc. in Transaction Involving Carbetocin Patent Rights and Technology

Pryor Cashman client Marina Biotech, Inc. (Nasdaq: MRNA), a leading RNAi-based drug discovery and development company, announced on August 26, 2010 the consummation of the sale of patent rights and technology related to Carbetocin to Cypress Bioscience, Inc.

Carbetocin is a long-acting analog of oxytocin, a naturally produced hormone that may benefit individuals with autism.

Pryor Cashman acted as Marina Biotech's legal advisor in the transaction. The Pryor Cashman team was composed of Partner Stephen M. Goodman and associate Danielle Schechner.